Human Genomics

Researchers from Osaka University examined how disease severity is evaluated in the context of preimplantation genetic testing for single-gene diseases (PGT-M) by conducting case studies of the regulatory frameworks governing PGT-M in Japan, the United Kingdom, and Western Australia through analysis of relevant policy documents. Results of their study showed that how policies define the standard for disease severity that would justify PGT-M and how decisions are made regarding the eligibility of individual cases have important social and ethical implications.